Thyrotoxic atrial fibrillation

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Atrial fibrillation is a common cardiac complication in hyperthyroidism, affecting up to 15% of patients.
• Hyperthyroidism significantly increases the risk of thromboembolism, particularly affecting the central nervous system.

Observation:

• Patients with thyrotoxic atrial fibrillation often require oral anticoagulation to prevent thromboembolic events.
• Hyperthyroidism alters drug metabolism, necessitating dose adjustments for rate-controlling agents due to increased clearance.
• Warfarin dosage requires reduction in these patients because hyperthyroidism accelerates the clearance of vitamin K-dependent clotting factors.

Findings:

• Thyrotoxicosis-induced atrial fibrillation presents unique management challenges.
• Pharmacokinetic changes in hyperthyroidism impact the efficacy and safety of commonly used medications.

Implications:

• Optimizing anticoagulation and rate control is crucial for managing thyrotoxic atrial fibrillation.
• This review provides a summary of clinical management strategies for this patient population.
• Understanding drug interactions and metabolic changes is key to effective treatment.